Evidence map›Paper›PMID 41221514›Full record

ArticleFrontiers in medicine2025

Unraveling the genetic links between obesity or insulin resistance and breast cancer through the impact of CD295 and ITLN1 SNPs with DNA damage in a case-controlled study with bioinformatics analysis.

Nadia M Hamdy, Yasser O Mosaad, Reham Elshimy, Ahmad A Hady, Queran Lin, Zayd Jastaniah, Razan Amjad, Huda Altoukhi, Hatim Almarzouki, Ahmed Abdelsamad and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nadia M HamdyDepartment of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Yasser O MosaadDepartment of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy, Future University in Egypt (FUE), New Cairo, Egypt.
Reham ElshimyDepartment of Clinical and Chemical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.
Ahmad A HadyDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Queran LinDepartment of Primary Care and Public Health, Faculty of Medicine, WHO Collaborating Centre for Public Health Education and Training, School of Public Health, Imperial College London, London, United Kingdom.
Zayd JastaniahDepartment of Internal Medicine, Faculty of Medicine, King Abdulaziz University (KAU), Rabigh, Saudi Arabia.
Razan AmjadDepartment of Internal Medicine, Faculty of Medicine, King Abdulaziz University (KAU), Rabigh, Saudi Arabia.
Huda AltoukhiRadiotherapy Unit, Department of Radiology, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Hatim AlmarzoukiRadiotherapy Unit, Department of Radiology, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Ahmed AbdelsamadDepartment of Surgery II, University of Witten/Herdecke, Witten, Germany.
Hekmat M El MagdoubDepartment of Biochemistry, Faculty of Pharmacy, Misr International University, Cairo, Egypt.
Doaa FathiDepartment of Biochemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mutations in the cluster of differentiation (CD) 295 gene, which encodes a class I cytokine receptor, are associated with obesity and breast cancer (BC). Single-nucleotide polymorphisms (SNPs) in the adipocyte-inferred novel cytokine intelectin 1 (ITLN1) remain understudied in connection to CD295 polymorphisms and diabetes mellitus (DM) or a pre-diabetic state, as well as to DNA damage seen in BC. Aim: To explore whether CD295 (rs6700986) and ITLN1 (rs952804) SNPs impact BC with or without DM, insulin resistance (IR), or obesity. Effects of ITLN1 or CD295 polymorphism(s) on DNA damage in BC were also examined. All of these are to be confirmed by bioinformatics/ Subjects and methods: Blood samples from 170 women with BC (including 33 and 48 with DM and pre-diabetes, respectively) and from 108 age-matched women in the control group were collected. Plasma insulin, leptin, CD295, and ITLN1 levels were measured by ELISA. rs6700986 and rs952804 were analyzed by RT-PCR. DNA damage was assessed using the alkaline comet assay. Results: BC cases with clinical stage T II and positive LN, as well as tumor histologic grade III, presence of obesity, pre-diabetic events, DM, or IR, were associated with CD295 rs6700986 mutant homozygous (CC) and heterozygous (CT) genotypes and ITLN1 rs952804 mutant CT genotype ( Conclusion: CD295 (rs6700986) and ITLN1 (rs952804) SNPs should be considered as BC-associated susceptibility risk factors in obese, insulin resistance, or pre-diabetic individuals.

Indexed as

bioinformatics/in silicobreast cancer (BC)CD295cytokines/inflammationITLN1obesity/insulin resistance (IR)/diabetes mellitus (DM)polymorphism/mutations

Identifiers

PMID41221514
PMCPMC12598017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.